<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821079</url>
  </required_header>
  <id_info>
    <org_study_id>B1731014</org_study_id>
    <nct_id>NCT01821079</nct_id>
  </id_info>
  <brief_title>A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation</brief_title>
  <official_title>A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation Of Pf-05175157 And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in healthy volunteers is to assess the relative bioavailability of
      PF-05175157 as powder-in-capsule and a tablet formulation and the effect of food on the
      pharmacokinetics of the tablet formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0 to 72 H after dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)</measure>
    <time_frame>0 to 72 H after dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0 to 72 H after dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum plasma concentration is observed (Tmax)</measure>
    <time_frame>0 to 72 H after dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>0 to 72 H after dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PF-05175157 PIC in fed state</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg single dose of PF-05175157 administered as PIC in the fed state (following a standard high fat meal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05175157 tablet in fed state</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05175157 tablet in fed state (repeat)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05175157 tablet in fasted state</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg single dose of PF-05175157 administered as tablet formulation in the fasted state (following at least a 10 hour fast).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)</description>
    <arm_group_label>PF-05175157 PIC in fed state</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)</description>
    <arm_group_label>PF-05175157 tablet in fed state</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)</description>
    <arm_group_label>PF-05175157 tablet in fed state (repeat)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)</description>
    <arm_group_label>PF-05175157 tablet in fasted state</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive

          -  Women must be of non childbearing potential

          -  Body Mass Index (BMI) of 25 to 35 kg/m2; and a total body weight &gt;50 kg (110 lbs)

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal
             allergies at time of dosing) disease or clinical findings at Screening.

          -  Active ocular disease including infection, glaucoma, seasonal allergies, dry eye
             symptoms, optic nerve disease or retinal disease.

          -  History of habitual smoking in the past 5 years or history or evidence of habitual use
             of other (non smoked) tobacco or nicotine-containing products within 3 months of
             Screening or positive cotinine test at Screening or Day 0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731014&amp;StudyName=A%20Healthy%20Volunteer%20Study%20To%20Assess%20Relative%20Bioavailability%20Of%20Powder-In-Capsule%20And%20A%20Tablet%20Formulation%20And%20The%20Effect%20Of%20Food%20On%20T</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <last_update_submitted>May 20, 2013</last_update_submitted>
  <last_update_submitted_qc>May 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single dose</keyword>
  <keyword>Relative Bioavailability</keyword>
  <keyword>Food effect</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

